Specificity of Effector Activation by Rho Family GTPases
Specificity of Effector Activation by Rho Family GTPases
批准号:
8144248
负责人:
JEFFREY R PETERSON
金额:
$30.78万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-09-30 至 2013-08-31
关键词:
AffinityBindingBiochemicalBiologicalBiological ModelsCell physiologyCellsClinical PathwaysComputer SimulationCultured CellsDataDiseaseDrug Delivery SystemsEnzymesFamilyFutureGTP-Binding ProteinsGoalsGuanine Nucleotide Exchange FactorsGuanosine TriphosphateGuanosine Triphosphate PhosphohydrolasesHealthHumanImmune System DiseasesIn VitroIndividualKineticsMalignant NeoplasmsMammalian CellMeasuresMediatingMental RetardationMolecularMonitorMonomeric GTP-Binding ProteinsMusNeoplasm MetastasisPathway interactionsPhosphorylationProcessProteinsRegulationRoleScaffolding ProteinSignal PathwaySignal TransductionSpecificitySystemTestingValidationWiskott-Aldrich SyndromeWorkXenopusXenopus laevisbaseeggin vitro Modelinhibitor/antagonistnovelnovel therapeutic interventionoverexpressionp21 activated kinaseras-Related G-Proteinsresearch studyresponserhorho GTP-Binding Proteinsscaffoldsmall moleculetumortumorigenesis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The Ras-related GTPases Rac and Cdc42 contribute to tumorigenesis and metastasis through the activation of diverse downstream effector proteins but how cells regulate activation of distinct subsets of effectors in different contexts is unknown. We have found that the number of Rac and Cdc42 molecules in cells is greatly exceeded by the total number of effector molecules and propose that competition between effectors must limit effector activation. This hypothesis is critically important because competition between effectors implies that loss or overexpression of an individual effector, such as can occur in cancer or Wiskott-Aldrich syndrome, would alter signaling by other pathways. This concept of an interconnected effector network, as opposed to distinct pathways that operate independently, has profound implications for the molecular basis of these diseases. Thus, understanding the interrelations of effector signaling pathways is crucial for predicting biological responses to pharmacological strategies targeting individual effector pathways. The goal of this proposal is to explicate the regulatory mechanisms controlling the specificity of effector activation by Rac and Cdc42. We have developed an experimental system using cytoplasmic extracts of Xenopus laevis eggs in which endogenous Rac and Cdc42 can be activated in a tunable manner and the activation of endogenous downstream effectors N-WASP and the p21-activated kinases (Paks) can be measured quantitatively. Our central hypothesis, based on preliminary studies, is that superimposed on a background of simple competition between effectors, two regulatory mechanisms bias effector activation; scaffolding proteins and pathway crosstalk. In our first aim we will determine the importance of competition on Rac/Cdc42 effector activation by modestly modulating protein levels of individual effectors and measuring the activation of others. In the second aim we will elucidate the role of a scaffolding protein, Toca-1, in biasing Rac/Cdc42 effector selection and will determine if guanine nucleotide exchange factors can serve as scaffolding factors to bias effector pathway activation. In the third aim we will illuminate the role of crosstalk in regulating Rac/Cdc42 effector selection by determining if phosphorylation of N- WASP by Paks regulates N-WASP activation by Rac/Cdc42. These studies will reveal fundamental mechanisms of signaling specificity that likely apply to other small GTPases, such as Ras, that activate multiple downstream pathways of clinical importance in cancer. PUBLIC HEALTH RELEVANCE: The Rho family GTPases Rac and Cdc42 regulate many other proteins that can contribute to the disease process in cancer, mental retardation, and immune disorders. Although many of the partners of Rac and Cdc42 are known, we do not know how the regulation of the various partners is coordinated. This proposal will illuminate how this coordination could be corrupted in disease and will provide crucial information for the selection of optimal drug targets for new therapeutic approaches.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Small Molecule Inhibitors of the Poxvirus Type I Interferon Binding Protein
-
批准号:8539743
-
项目类别:
-
资助金额:$20.97万
-
财政年份:2012
-
负责人:JEFFREY R PETERSON
-
依托单位:
Small Molecule Inhibitors of the Poxvirus Type I Interferon Binding Protein
-
批准号:8401099
-
项目类别:
-
资助金额:$24.35万
-
财政年份:2012
-
负责人:JEFFREY R PETERSON
-
依托单位:
RHO PROTEINS AND MASS SPECTROMETRY
-
批准号:8168766
-
项目类别:
-
资助金额:$0.02万
-
财政年份:2010
-
负责人:JEFFREY R PETERSON
-
依托单位:
Specificity of Effector Activation by Rho Family GTPases
-
批准号:7935555
-
项目类别:
-
资助金额:$22.93万
-
财政年份:2009
-
负责人:JEFFREY R PETERSON
-
依托单位:
Kinase-dependent Regulation of Metabolic Enzymes
-
批准号:9700784
-
项目类别:
-
资助金额:$3.68万
-
财政年份:2008
-
负责人:JEFFREY R PETERSON
-
依托单位:
Kinase-dependent Regulation of Metabolic Enzymes
-
批准号:9278189
-
项目类别:
-
资助金额:$36.14万
-
财政年份:2008
-
负责人:JEFFREY R PETERSON
-
依托单位:
Specificity of Effector Activation by Rho Family GTPases
-
批准号:7685476
-
项目类别:
-
资助金额:$31.41万
-
财政年份:2008
-
负责人:JEFFREY R PETERSON
-
依托单位:
Specificity of Effector Activation by Rho Family GTPases
-
批准号:7924893
-
项目类别:
-
资助金额:$31.1万
-
财政年份:2008
-
负责人:JEFFREY R PETERSON
-
依托单位:
Kinase-dependent Regulation of Metabolic Enzymes
-
批准号:9145229
-
项目类别:
-
资助金额:$34.92万
-
财政年份:2008
-
负责人:JEFFREY R PETERSON
-
依托单位:
Specificity of Effector Activation by Rho Family GTPases
-
批准号:7524479
-
项目类别:
-
资助金额:$31.26万
-
财政年份:2008
-
负责人:JEFFREY R PETERSON
-
依托单位:
Specificity of Effector Activation by Rho Family GTPases
-
批准号:8325714
-
项目类别:
-
资助金额:$30.78万
-
财政年份:2008
-
负责人:JEFFREY R PETERSON
-
依托单位:
Allosteric, Small-Molecule Inhibitors of Actin Nucleation by the Formin mDia1
-
批准号:7680730
-
项目类别:
-
资助金额:$5.0万
-
财政年份:2007
-
负责人:JEFFREY R PETERSON
-
依托单位:
Allosteric, Small-Molecule Inhibitors of Actin Nucleation by the Formin mDia1
-
批准号:7287634
-
项目类别:
-
资助金额:$20.67万
-
财政年份:2007
-
负责人:JEFFREY R PETERSON
-
依托单位:
ACTIN ASSEMBLY BY PHOSPHOINOSITIDES & CDC42
-
批准号:6125230
-
项目类别:
-
资助金额:$3.24万
-
财政年份:1999
-
负责人:JEFFREY R PETERSON
-
依托单位:
ACTIN ASSEMBLY BY PHOSPHOINOSITIDES & CDC42
-
批准号:2709608
-
项目类别:
-
资助金额:$2.5万
-
财政年份:1998
-
负责人:JEFFREY R PETERSON
-
依托单位:
ACTIN ASSEMBLY BY PHOSPHOINOSITIDES & CDC42
-
批准号:6329590
-
项目类别:
-
资助金额:$4.02万
-
财政年份:1998
-
负责人:JEFFREY R PETERSON
-
依托单位:
国内基金
海外基金
登录
查看更多内容
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:32170319
-
项目类别:面上项目
-
资助金额:58.00万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:--
-
项目类别:--
-
资助金额:58万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
-
批准号:31672538
-
项目类别:面上项目
-
资助金额:62.0万元
-
批准年份:2016
-
负责人:孙跃峰
-
依托单位:
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
-
批准号:31372080
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:杨迎伍
-
依托单位:
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
-
批准号:81172529
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:杨其峰
-
依托单位:
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
-
批准号:81070952
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2010
-
负责人:刘师莲
-
依托单位:
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
-
批准号:30672361
-
项目类别:面上项目
-
资助金额:24.0万元
-
批准年份:2006
-
负责人:徐宁志
-
依托单位: